期刊
BIOLOGY OF THE NEONATE
卷 77, 期 -, 页码 2-8出版社
KARGER
DOI: 10.1159/000047050
关键词
pulmonary surfactants; surfactant proteins; acute respiratory distress syndrome; meconium aspiration; dextrans; polyethylene glycols
类别
The treatment of neonatal respiratory distress syndrome with surfactant represents a successful culmination of decades of basic and clinical research. In many babies, respiratory distress syndrome is a relatively pure expression of surfactant deficiency, Acute respiratory distress syndrome (ARDS) is a more common disease that is most frequently seen in adults, but the processes are common to lung injuries in newborns and children as well. While some impairment of production and secretion of surfactant constituents may be present in ARDS, surfactant inactivation is probably a more important factor in this disease. Until recently, surfactants available for human use have been easily susceptible to inactivation and this may explain why they have been less successful for treatment of ARDS than for neonatal respiratory distress syndrome. This review outlines recent information on surfactant inactivation and describes initiatives that may result in 'inactivation-proof surfactants that may be of increased benefit in ARDS. Copyright (C) 2000 S. Karger AG. Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据